The Bronx, NYNCT05799274Now EnrollingIRB Ready

Healthy Volunteers Clinical Trial in The Bronx, NY

Access cutting-edge healthy volunteers treatment through this clinical trial at a research site in The Bronx. Study-provided care at no cost to qualified participants.

Sponsored by Radiopharm Theranostics, Ltd

Quick Self-Assessment

See if you qualify for this The Bronx location

Preparing your pre-screening questions…

Expert Care in The Bronx

Access healthy volunteers specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related healthy volunteers treatment provided free

Apply for This The Bronx Location

Check if you qualify for this healthy volunteers clinical trial in The Bronx, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to The Bronx

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit The Bronx site if eligible
  4. 4Begin participation

About This Healthy Volunteers Study in The Bronx

This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors

Sponsor: Radiopharm Theranostics, Ltd

Who Can Participate

Inclusion Criteria

Must be ≥ 18 years of age at the time of informed consent.
All participants must be willing and able to give informed consent.
For patients with cancer: have a history of histologically or cytologically confirmed PDAC, non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma, cervical cancer, endometrial cancer, or ovarian cancer and have had a SOC CT or MRI within 12 weeks prior to giving consent that indicates the presence of at least 1 site of new or residual disease. If the SOC CT or MRI has occurred prior to 12 weeks, consultation with the Sponsor must be sought prior to patient enrollment. SOC images must be available for submission to the centralized imaging reader as reference.
Screening laboratory values within 30 days prior to administration of the study drug:
WBC ≥ 1200/μL
ANC ≥ 1000/μL
Platelets ≥ 75,000/μL
Hemoglobin ≥ 9.0 g/dL
Creatinine ≤ 1.5 mg/dL
AST/ALT ≤ 3 x ULN for patients with no liver metastases.
AST/ALT ≤ 5 x ULN for patients with liver metastases.
Bilirubin ≤ 1.5 mg/dL except for participants with Gilbert's disease.
Patients should have a life expectancy of ≥ 12 weeks as judged by the Investigator.
All participants must have baseline pulse oximetry ≥ 95% on room air.
Unremarkable ECGs, with PR intervals of less than 200 msec and QTcF intervals (corrected with Frederica's method) of less than 450 msec.
Willing to refrain from taking illicit drugs one week prior to PET scanning and through the follow-up phone call on Day 3 (+2 days).
Willing to refrain from donating blood for 4 weeks after administration of RAD301.
Have not participated in any other research study that requires taking medication within 4 weeks (or 10 half-lives, whichever is shorter) from the time of informed consent to the end of the Imaging and Safety Follow-Up Period. Previous or ongoing participation in another study should be discussed with the Sponsor.

Exclusion Criteria

Participant may not be a member of a vulnerable population defined as participants who are not able to understand the nature of the trial and provide informed consent or who have any medical, psychological or sociological condition that in the opinion of the investigator would interfere with the ability to give consent or interfere with protocol compliance.
Women may not be pregnant or breastfeeding. Women of childbearing potential must have a negative urine pregnancy test within 72 hours prior to administration of RAD301.
History of an anaphylactic reaction to a protein- or peptide-derived therapeutic or a diagnostic agent.
History, physical examination, or clinical laboratory tests suggestive of a condition, disorder, or disease that could adversely affect drug absorption, distribution, metabolism, or elimination of RAD301, including chronic liver or renal failure.
Unable to tolerate the study procedures.
Patients with brain metastases are eligible as long as there is no requirement for high doses of systemic corticosteroids that could result in immunosuppression (\>10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration. An MRI is not required to rule out brain metastases or leptomeningeal metastases
Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, or interfere with the interpretation of study results.
Clinically significant cardiovascular/ cerebrovascular disease defined as cerebral vascular accident, stroke, carotid artery disease transient ischemic attach (\< 6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class \>II) or serious cardiac arrhythmia.
Other than the tumor types being studied, a prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix or breast.
Participants with active, known or suspected autoimmune disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
Participants who underwent major surgery within 4 weeks of administration of study drug (not including diagnostic laparoscopy).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in The Bronx?

Yes, this clinical trial (NCT05799274) has an active research site in The Bronx, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Healthy Volunteers Treatment Options in The Bronx, NY

If you're searching for healthy volunteers treatment options in The Bronx, NY, this clinical trial (NCT05799274) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our The Bronx research site is actively enrolling participants for this clinical trial. You'll receive care from experienced healthy volunteers specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Ready to Join in The Bronx?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · The Bronx, NY